Assessment of Dexketoprofen Trometamol on Tibia Development in Chicken Embryos
Öz
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed analgesics, but their teratogenic potential remains understudied. Dexketoprofen trometamol (DT), commonly used clinically, lacks sufficient data con-cerning fetal skeletal development safety. This study investigated the effects of DT on tibial growth and growth plate structure in chicken embryos.
Methods: The experiment had two phases. Initially, embryos were administered either saline solution (control) or 0.084 mg/0.1 mL DT. In the second phase, embryos were divided into five groups: minimum DT dose (0.042 mg), maximum DT dose (0.126 mg), double maximum dose (0.252 mg), alcohol control, and saline control. Eggs were incubated for seven days before morphometric and histopathological analyses. Statistical tests included Fisher's exact test, one-way ANOVA, and Kruskal–Wallis analysis.
Results: In phase one, embryo viability at day 7 showed no significant difference between DT and control groups. In the second phase, embryos receiving minimum and maximum DT doses demonstrated improved developmental outcomes compared to the double maximum dose and control groups. Specifically, crown–rump lengths significantly increased in the maximum dose compared to the double maximum group (p=0.015). Tibial lengths were also superior in the maxi-mum dose group compared to saline controls. Growth plate proliferative zone cell counts were higher in minimum and maximum dose groups versus controls, notably exceeding the double maximum dose group. No significant changes appeared in tibia diameter, ossification center length, or hypertrophic zone cell counts.
Conclusion: DT showed no harmful impact on chicken embryo tibial development at the adult recommended dose in viable embryos. These findings also provide insight into the potential risk of embryotoxic effects of DT, particularly at supratherapeutic exposure levels where growth-related endpoints were less favorable. However, further molecular and clinical investigations are necessary.
Anahtar Kelimeler
Bone Development, Abnormalities, Drug-induced, Embryo development, Dexketoprofen Trometamol, Tibia
Destekleyen Kurum
yok
Etik Beyan
Bu çalışma, Kahramanmaraş Sütçü İmam Üniversitesi (KSÜ) Ziraat Fakültesi Hayvan Deneyleri Yerel Etik Kurulu'nun onayı ile yürütülmüştür (Tarih:21.02.2020-Sayı:2020/02-03). Gerekli tüm işlemler Ziraat Fakültesi Zootekni Bölümü Tavukçuluk Araştırma Laboratuvarı'nda gerçekleştirilmiştir. Çalışmada kullanılan makroskobik ve histopatolojik değerlendirmeler Mustafa Kemal Üniversitesi Tayfur Ata Sökmen Tıp Fakültesi Hastanesi Tıbbi Patoloji Anabilim Dalı'nda gerçekleştirilmiştir.
Teşekkür
yok
Kaynakça
- Moore KL, Persaud TVN, Torchia MG. The Developing Human: Clinically Oriented Embryology. 9th ed. Philadelphia, PA: Saunders; 2011.
- Schaefer C, Peters PWJ, Miller RK, editors. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. 3rd ed. Amsterdam: Academic Press; 2014.
- Van Gelder MM, Van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N. Teratogenic mechanisms of medical drugs. Hum Reprod Update. 2010;16(4):378-94.
- Vaudin P, Augé C, Just N, Mhaouty-Kodja S, Mortaud S, Pillon D. When pharmaceutical drugs become environmental pollutants: Potential neural effects and underlying mechanisms. Environ Res. 2022;205:112495.
- Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol. 2005;193(3 Pt 1):771-7.
- Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Non-steroidal anti-inflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40(5):824-9.
- Ofori B, Oraichi D, Blais L, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006;77(4):268-79.
- Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Dolores Pilloni M, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474-90.
- U.S. Food and Drug Administration. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. FDA Drug Saf Commun. 2020 Oct 15:1-9.
- Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther. 2006;8(4):215.